Evidence map›Paper›PMID 39844808›Full record

ArticleSurgery in practice and science2023

Outcomes of trauma patients on chronic antithrombotic therapies in a trauma center in a rural state.

Benjamin Moore, Hanna Jensen, Karan Patel, Zeel Modi, Rebecca J Reif, Shibani Lal, Stephen M Bowman, Melissa Kost, Kyle J Kalkwarf, Joseph Margolick and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgery in practice and science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Benjamin MooreCollege of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Hanna JensenDivision of Trauma and Acute Care Surgery, Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Karan PatelCollege of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Zeel ModiCollege of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Rebecca J ReifCollege of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Shibani LalCollege of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Stephen M BowmanCollege of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Melissa KostDivision of Trauma and Acute Care Surgery, Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Kyle J KalkwarfDivision of Trauma and Acute Care Surgery, Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Joseph MargolickDivision of Trauma and Acute Care Surgery, Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Avi BhavarajuDivision of Trauma and Acute Care Surgery, Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Howard L CorwinCritical Care Medicine, Geisinger Medical Center, Danville, PA, USA.

Funding

Expanding Translational Research in ArkansasUL1TR003107 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI JAMES, LAURA P · 2019 to 2023
$21.6M
NCATS NIH HHS UL1 TR003107
6 · The paper itself

Abstract

Objective: The number of trauma patients presenting with chronic antithrombotic therapy is on the rise. The risk of hemorrhage, the leading cause of death in trauma patients, increases for those on such therapy. This study sought to compare the clinical outcomes of patients on warfarin, direct oral anticoagulants (DOAC), or antiplatelet agents. Methods: A retrospective cohort analysis was conducted on adult patients admitted to a Level 1 trauma center with pre-admission antithrombotic therapy. Patients were divided into those on warfarin, DOACs, and antiplatelet agents. The primary outcomes measured were hospital mortality, total blood products received, hospital length of stay (LOS), and ICU LOS. Results: 738 patients were included in the study: 191 (26 %) warfarin, 260 (35 %) DOACs, and 287 (39 %) antiplatelet. There were no differences in the demographic variables between study groups. The Injury Severity Score (ISS) was similar across the three groups as well as blood product usage, reversal agent usage, and mean hospital stay. Multivariable regression showed patients with pre-admission antiplatelet usage were more likely to have a shorter ICU LOS than those on warfarin ( Conclusion: Blood product and reversal agent use was similar between patients on warfarin, DOACs, or antiplatelet agents. Patients on antiplatelet agents had a shorter ICU stay than the warfarin group, the only significant difference observed. Our results indicate similar safety profiles of antithrombotic medications in a generic trauma population, likely due to institutional protocols to increase responsiveness and immediate availability of resources when the patient has known anticoagulation.

Indexed as

AnticoagulationAntithrombotic medicationClinical outcomesRetrospective reviewTraumatic injury

Identifiers

PMID39844808
PMCPMC11749949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.